Join MySLAS Social


Medicinal Chemical Facilities

Lead Discovery Center

Institution Max Planck Drug Discovery Center
Contact Name Thomas Hegendoerfer, Head of Business Development & Operations
Contact Email
Main Website Visit Main Website
Hit Selection and Optimization Services - Hit Triage
- Patent Analysis
- Computational Filtering
- Structure-based Drug Design
Other Hit Selection and Optimization Services Computer-aided rational drug design, cheminformatics, Design of focused compound libraries, Assay Development & Screening
Lead Selection and Optimization Services - Custom-Designed Analog Synthesis
- Solubility Assessment
- Protein Binding Assessment
- Microsomal Stability Assessment
- Permeability Assessment
- Pharmacokinetic Studies
- In Vivo Efficacy Studies
- Drug Metabolism Studies
- In Vitro Toxicology Studies
Other Lead Selection and Optimization Services in vitro and in vivo Pharmacology, ADMET, Establishment of structure-activity and structure-property relationships (SAR, SPR) and pharmacophore models, Hit-to-lead identification, based on biochemical or cellular active compounds, preliminary tox and tolerance studies, lead to candidate optimization
Scale-up Synthetic Capabilities for Hits/Analogs 10 g
Can the facility support in silico screening? Yes
Is the facility open to projects not affiliated with host institution? Yes
Is data collected in this facility publicly available? Varies by project
Additional Comments The LDC provides customized solutions for every project, working closely together with its vast academic and industrial network. In addition to the LDC’s own state-of-the-art facilities, a range of diverse technologies and resources can be accessed via prime research institutes and service providers, for example: compound libraries, high throughput screening (HTS), animal models, structural biology, bio- and cheminformatics or protein production. In addition, the LDC works closely with inventors to integrate their specific expertise and to draw on their unique tools, technologies, models, methods and materials. In cooperation with academic and industrial partners, the LDC selects promising early-stage projects from public research institutions – including the Max Planck Society and renowned universities – and professionally transforms them into biopharmaceutical development projects. The results are innovative leads that meet the state-of-the-art standards of the pharmaceutical industry, which then further advance the lead compounds into clinical development and to the market. The academic partners are involved throughout the entire project until commercialization, which ensures that the gap between science and industry is truly closed.